The importance of lowering blood pressure (BP) in hypertensive subjects is well known but the relationship between hypertension and cognitive function is controversial. This article reviews the role of hypertension in the aetiology of cognitive impairment and the relationships between BP, cerebral perfusion and cognition. It also summarizes findings of studies addressing the effect of antihypertensive therapy and cognition. An electronic database search of MEDLINE, EMBASE and the Cochrane Library and extensive manual searching of articles were conducted to identify studies that have used objective measurements of BP and neuropsychological tests to investigate the relationship among hypertension, cognitive function and/or antihypertensive treatment. In total, 28 cross-sectional studies, 22 longitudinal studies and 8 randomized placebo-controlled trials met the inclusion criteria. Cross-sectional studies showed mixed relationships between higher BP and cognition, with many studies showing no correlation or even J-or U-shaped associations. The majority of longitudinal studies demonstrated elevated BP to be associated with cognitive decline. Randomized studies demonstrated heterogeneous and, sometimes conflicting, effects of BP lowering on cognitive function. Suggested reasons for this heterogeneity include multiple mechanisms by which hypertension affects the brain, the variety of cognitive instruments used for assessment and differences in antihypertensive treatments. Although lowering the BP is beneficial in most patients with vascular risk factors, the effects of BP reduction on cognition remain unclear. Given the predicted upswing in people with cognitive impairments, the time is right for randomized clinical trials with specific cognitive end points to examine the relationship between cognitive function and hypertension and guide practice.
Introduction
The role of hypertension in the aetiology of vascular disease and the beneficial effects of antihypertensive treatment are well established. 1, 2 There is evidence to suggest that antihypertensive treatment may reduce stroke and cerebral white matter disease even in individuals with blood pressure (BP) below the current accepted threshold for treatment. 3, 4 Although this suggests that lower BPs should preserve cognitive function, the relationship between BP and cognition is a subject of much discussion. In this article, we examine the physiological mechanisms underlying the relationship between hypertension and cognitive function. We also summarize the findings from epidemiological studies and randomized clinical trials addressing the relationship of BP and antihypertensive therapy to cognitive function and consider the implications of these findings for future management.
Hypertension and cognition
Hypertension accelerates arteriosclerotic changes in the brain predisposing to atheroma formation in large diameter blood vessels and arteriosclerosis and arteriolar tortuosity of small vessels of the cerebral vasculature. 5 These vascular changes, incorporating medial thickening and intimal proliferation, result in a reduction of luminal diameter, increased resistance to flow and decline in perfusion. 6 Such hypoperfusion can produce discrete regions of cerebral infarction and diffuse ischaemic changes in the periventricular and deep white matter (leukoaraisosis) causing vascular cognitive impairment and also contribute to the pathogenesis of Alzheimer's disease by destabilizing neurons and synapses. 7, 8 Indeed, neuropathological studies have linked atherosclerotic burden in the brain to the pathological changes of both Alzheimer's disease and vascular cognitive impairment. 9, 10 Alzheimer's disease and vascular cognitive impairment are the two most common causes of cognitive impairment with the former characterized by early loss of episodic memory and the latter typically involving impairment of attention, information processing and executive function. 11 It has been suggested that decreased BP reduces mechanisms contributing to Alzheimer's disease and generalized neurodegenerative changes, which may account for improvements in impairments on memory tasks. 12 Impairments of attention, perceptual processing and executive function, on the other hand, reflect more specific damage to deep subcortical white matter circuits, many of which are located in the internal watershed area of the frontal lobe. 13 Chronic hypertension has a disproportionate effect on these areas because accelerated arteriosclerotic changes of non-communicating perforating arteries may not be reversible by BP reduction once these changes are established.
14 Furthermore, episodic or sustained hypotension, and possibly excessive treatment of hypertension, may induce cerebral hypoperfusion, ischaemia and hypoxia that may in turn compromise neuronal function and eventually evolve into a neurodegenerative process.
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Methods
In January 2008, an electronic database search was performed of MEDLINE, EMBASE and the Cochrane Library using the following MeSH and keywords: BP, hypertension, hypertensive, antihypertensive, cognition, cognitive function, cognitive performance, intellect, intellectual function, neuropsychological and psychomotor. The resultant information was supplemented by extensive manual searching of references ( Figure 1 ). Studies investigating the relationships between BP and cognitive function, measured with various neuropsychological tests, were examined, whereas studies assessing the relationship between BP and dementia, diagnosed on the basis of clinical assessment scales, were excluded. Studies that did not use neuropsychological tests as outcome measures were excluded to maintain homogeneity in the presentation of findings from the literature.
Cognitive outcome measures
Neuropsychological tests are standardized techniques that yield quantifiable and reproducible results that are referable to the scores of normal persons of age and demographic background similar to those of the individual being tested. A wide selection of tests exist, each of differing sensitivity and specificity for particular brain function deficits. In general, simple tests that elicit discrete responses are valuable in determining focal brain damage, whereas assessments of particular cognitive domains are useful in characterizing the neuropsychological profile of specific neurodegenerative processes. On the other hand, multi-dimensional tests, being dependent upon several aspects of cerebral function, tend to be nonspecific but very sensitive to changes in general intellect and mental efficiency.
Epidemiological studies
Many cross-sectional studies have assessed the relationship of BP and cognition (Table 1) . These studies have showed conflicting relationships between cognitive function and BP with positive and negative associations, and J-and U-shaped relationships being demonstrated in addition to five studies reporting no significant association between BP and cognition. Most studies were populationbased, involving a large number of subjects. However, studies varied in their exclusion criteria, classification of hypertension and range of BP values of the participating individuals. Cognitive function was assessed using different neuropsychological instruments; 15 studies used a cognitive battery covering various cognitive domains and 16 used measures of global cognition such as the minimental state examination. All but two studies 26, 38 adjusted for age, gender and education but other studies varied in additional covariates (such as vascular risk factors) included in multivariate analyses.
Cross-sectional studies are limited in determining the direction of an association because both exposure and outcome are assessed simultaneously. Longitudinal studies have therefore been suggested to be more appropriate in assessing the relationship between BP and cognitive function, but they remain time dependent. The majority of longitudinal studies demonstrated elevated BP to be associated with cognitive decline 25, 31, [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] but some studies showed quadratic, J-and U-shaped relationships between BP and cognitive performance 33, 45, [59] [60] [61] in addition to three studies showing elevated BP to be associated with improved cognitive performance 27, 43, 49 ( Table 2 ). Sample sizes ranged from 155 to 10 963 and duration of follow-up ranged from 1.5 to 30 years. Studies also differed in their inclusion and exclusion criteria, BP levels of participating individuals and use of antihypertensive treatments. Again, a variety of cognitive measures were employed with 12 studies using a battery of neuropsychological tests designed to assess different cognitive domains and 16 studies using measures of global cognition. All but one study 59 adjusted for age, gender and education but studies varied in additional covariates, particularly the use of antihypertensive treatments, included in multivariate analyses.
A number of different genetic, demographic and atherosclerotic risk factors for cognitive impairment have been demonstrated in cross-sectional and longitudinal studies. 62 These factors may play an important role in driving the relationship between hypertension and cognition and were often not included as covariates in the analyses of the studies included in this review. Examples include ethnicity, hyperinsulinaemia and hyperhomocystinaemia that have been shown to have a significant impact on cognitive impairment in recent studies. [63] [64] [65] Furthermore, existing data suggest that the effect of hypertension on cognition may be affected by a patient's duration of hypertension and level of BP control in addition to the duration and choice of any antihypertensive treatment and again, these factors were often not taken into account in the analyses of these studies. 66 
Randomized controlled trials
Observational studies may demonstrate associations but do not determine causality; the latter only being shown by intervention studies. Only eight completed randomized placebo-controlled clinical trials of BP-lowering agents have reported the effects of treatment on the risk of cognitive impairment, and the effect of antihypertensive treatment on cognitive function remains a matter of debate (Table 3) . [67] [68] [69] [70] [71] [72] [73] [74] The Syst-Eur trial included a side project on 2418 subjects in whom cognitive function was assessed. Subjects were taking active treatment with nitrendipine ± enalapril and/or hydrochlorothiazide or placebo. The follow-up was only 2 years as the trial was terminated early because of significant differences in the incidence of stroke, the primary end point. Compared with placebo, active treatment reduced decline in mini-mental state examination score and lowered the incidence of dementia by 50% from 7.7 to 3.8 cases per 1000 patient-years. 71 The PROGRESS (Perindopril Protection against Recurrent Stroke Study) study randomized 6105 people with prior stroke or transient ischaemic attack to either active treatment with perindopril ±indapamide or matching placebo(s). After a mean follow-up of 3.9 years, cognitive decline occurred in 69, 70, 74 Three small trials (np69) with short follow-up duration (p7 months) added to the heterogeneity of demonstrated effects of BP lowering on cognition with both better and worse performance on different cognitive tests being shown in addition to an absence of significant effect. 67, 68, 72 We have previously undertaken a meta-analysis of the randomized controlled trials of BP reduction on cognitive function and demonstrated a heterogeneous effect of BP lowering on different aspects of cognitive function, with improvement in global cerebral function and memory tasks but impaired performance on perceptual processing and learning capacity tasks. 66 Many of the existing controversies on the cognitive consequences of BP lowering, especially in older people, arise from the design limitations of studies. Most studies did not quantify the level of cerebrovascular disease load in included subjects nor consider this a relevant prognostic determinant. Although only patients with previous strokes were included in the PROGRESS study, aetiological subtyping was not undertaken. Studies differed in subjects' age, BP, comorbidity, level of BP control, antihypertensive treatment, methods of neuropsychological assessment and trial duration, and many studies were not designed to address cognitive issues. Indeed, cognitive assessments were secondary outcome measures in most studies. Differences among studies in patient inclusion criteria and treatment protocols also confound interpretation of the literature. Furthermore, many studies allowed the use of b-blocker or centrally acting antihypertensive agents, despite such drugs having the potential to affect cognitive performance adversely. 75 
Summary
The results of cross-sectional studies investigating the relationship between BP and cognition showed conflicting relationships with positive, negative and J-and U-shaped associations. The majority of longitudinal studies demonstrated elevated BP to be associated with cognitive decline and a small number of randomized controlled trials demonstrated heterogeneous effects of BP lowering on cognitive function. These findings suggest a complex relationship between BP and cognitive function consistent with the biological mechanisms that exist. A variety of disease processes that are affected Cognitive function and hypertension J Birns and L Kalra by hypertension may result in cognitive impairment and the aetiology of cognitive impairment may influence specific domains of cognitive deficit. The need for different cognitive assessments for evaluating cognitive impairments of differing aetiology has been previously documented 14 and the different results shown in both epidemiological and intervention studies may in part be explained by use of a variety of cognitive instruments. Neuropsychological studies to date argue for comprehensive measurement of cognitive domains 76 and future studies investigating the relationships between cognitive function and hypertension will benefit from outcome measures that allow detection of deficits in specific cognitive domains.
BP lowering is beneficial in the vast majority of patients with vascular risk factors but the effect of BP reduction on cognition can only be assessed by randomized controlled trials including appropriate cognitive end points. The occurrence of lacunes and white matter changes increases exponentially after the age of 65 years 77 and as the baby boomer generation reaches the age of 65-70 years by 2015, we will experience the predicted upswing in cognitive impairment. Now is the time for randomized clinical trials to examine the relationship between cognitive function and hypertension.
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